Open Access Article
Ren-Xiao Lianga,
Ke Wanga,
Ling-Jie Songa,
Wei-Jian Shenga and
Yi-Xia Jia
*ab
aCollege of Chemical Engineering, State Key Laboratory Breeding Base of Green-Chemical Synthesis Technology, Zhejiang University of Technology, Chaowang Road 18#, Hangzhou 310014, China. E-mail: yxjia@zjut.edu.cn
bState Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, PR China
First published on 7th May 2019
An efficient palladium-catalyzed intramolecular deacetylative dearomatization reaction of 3-acetoxyindoles has been developed. A range of tetracyclic indolin-3-ones bearing C2-quaternary stereocenters are achieved in good yields, showing a wide substrate scope for this reaction. A preliminary enantioselective reaction is established to furnish the product in 63% ee by using (R,R,R)-phosphoramide-PE as a chiral ligand.
Transition-metal-catalyzed dearomatization of heteroarenes has become a reliable strategy to access heteroalicyclic compounds having carbon-based stereocenters on the ring.3 In this context, a number of dearomatizing transformations of indoles, benzofurans, pyrroles, and furans have been intensely established over the past few years.3,4 Amongst them, the palladium-catalyzed intramolecular dearomatizing arylation of indoles through a Heck reaction pathway has turned out to be very efficient in approaching fused- or spiro-indoline derivatives containing carbon stereocenters at C2 and/or C3 position of indoline ring. Documented examples included the intramolecular dearomatizing Heck reactions,5 reductive-Heck reactions,6 and domino dearomatizing Heck/anionic capture sequences involving the capture of benzyl-Pd species with a range of external nucleophiles,7 such as cyanide,7a organoboron reagents,7b–d alkynes,7e–h and azoles. Nevertheless, the aforementioned methods have not been applied to the construction of C2-disubstituted indolin-3-one substructure, which possesses a cyclic ketone unit at C3. On the other hand, the palladium-catalyzed dearomatizing cross-coupling of phenolates has recently been established as an powerful access to cyclohexenone molecules, in which keto–enol tautomerism of phenols under the basic conditions facilitates the dearomatization, rendering the formation of cyclic ketone motif reliable (Scheme 1a).8,9 Inspired by these transformations, as well as the Pd-catalyzed deacetylative arylation reactions of acetoxy-dihydronaphthalene derivatives developed by Zhou's group,10 we envisioned that a similar dearomatization of 3-acetoxyindole derivatives would provide a straightforward approach to C2-disubstituted indolin-3-ones. Herein, we report the palladium-catalyzed intramolecular deacetylative dearomatization of 3-acetoxyindoles, which results in tetracyclic indolin-3-one derivatives in good yields (Scheme 1b). It represents a new dearomatizing transformation of indoles.
:
1). Moreover, lowering the temperature remarkably decreased the yields even prolonging the reaction time to 48 h (62% for 80 °C and 30% for 60 °C, respectively).
| Entry | L | Base | Solvent | Yieldb (%) |
|---|---|---|---|---|
| a Reaction conditions: 1a (0.2 mmol), 5 mol% Pd(OAc)2, L (10 mol%), base (2.0 equiv.), H2O (2.0 equiv.), and solvent (2.0 mL) at 100 °C for 12 h.b Isolated yield.c No additional water and 100 mg 4 Å molecular sieves was added. | ||||
| 1 | PPh3 | K2CO3 | THF | 15 |
| 2 | PPh3 | K2CO3 | MeOH | ND |
| 3 | PPh3 | K2CO3 | 1,4-Dioxane | 20 |
| 4 | PPh3 | K2CO3 | Toluene | 10 |
| 5 | PPh3 | K2CO3 | DMF | 45 |
| 6 | PPh3 | K2CO3 | NMP | 40 |
| 7 | PPh3 | Na2CO3 | DMF | 54 |
| 8 | PPh3 | NaHCO3 | DMF | 24 |
| 9 | PPh3 | NEt3 | DMF | 46 |
| 10 | PPh3 | TMEDA | DMF | 20 |
| 11 | (o-Tol)3P | Na2CO3 | DMF | 50 |
| 12 | tBu3P·HBF4 | Na2CO3 | DMF | 30 |
| 13 | JohnPhos | Na2CO3 | DMF | 72 |
| 14 | tBu-XPhos | Na2CO3 | DMF | 84 |
| 15 | RuPhos | Na2CO3 | DMF | 75 |
| 16 | DavePhos | Na2CO3 | DMF | 65 |
| 17c | tBu-XPhos | Na2CO3 | DMF | 16 |
With the optimal reaction conditions in hand, we then investigated the scope of the intramolecular deacetylative dearomatization reaction. As shown in Scheme 2, a range of N-(2-iodobenzoyl)-3-acetoxyindoles were tested and all the reactions proceeded smoothly to afford the desired tetracyclic indolin-3-one products 2 in moderate to excellent yields. The analogous bromo-substrate led to a relatively lower yield (74%) of product 2a. Either electron-withdrawing or electron-donating substituents on the benzene ring of 2-iodobenzoyl moiety were well tolerated, furnishing indolin-3-ones 2b–2g in the yields ranging from 72% to 92%. The electron-donating substituents resulted in relatively higher yields. Note that a longer reaction time (18 h) was needed for the ortho-methyl product 2g. The effect of substituted groups attached on the indole ring was then examined. A range of functionalities at C5 of indole, including methyl, halide, methoxyl, –CF3, and –CO2Me, were compatible to this deacetylative dearomatization reaction, which smoothly delivered products 2h–2n in moderate to good yields, albeit relatively lower yields were observed for those substrates bearing electron-withdrawing substituents. It's worthy to note that a bromine atom of product 2l survived under the reaction conditions, which kept the potential for further functionalization. In addition, substrates having substituents at C6 also led to the desired products 2o–2q in good yields.
To demonstrate the synthetic utility of the reaction, several transformations of the indolin-3-one products were then conducted. A reduction of indolin-3-one 2a with LiAlH4 gave 3-hydroxylindoline 3 in 87% yield as a single isomer, which provides an efficient method to access tetracyclic indolin-3-ol in high diastereoselectivity (Scheme 3, eqn (1)). The Suzuki and Sonogashira reactions of product 2l having a bromide group were established, which furnished the coupling products 4 and 5 in 86% and 92% yields, respectively (Scheme 3, eqn (2) and (3)). The extended conjugate structure might find potential application as material molecules. In addition, a preliminary enantioselective reaction was also studied. As elucidated in Scheme 4, (R,R,R)-MONOPHOS-PE proved to be a potential ligand in the reaction of 1a′, leading to optically active indolin-3-one 2a in 63% ee albeit with a lower yield.
A tentative mechanism is depicted in Scheme 5. Considering the key role of water in this reaction (Table 1, entry 17), an initial hydrolysis of 3-acetoxy indole 1a in the presence of base is proposed to deliver 3-hydroxyindole I. An adduct II was then achieved through oxidative addition of Pd(0) to compound I. Facilitated by a base-mediated keto–enol tautomerism, nucleophilic attack of indole at C2 to Pd-center furnishes organopalladium III. Subsequent reductive elimination affords product 2a and fulfils the catalytic cycle.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 8.0 Hz, 1H), 7.49 (t, J = 7.4 Hz, 1H), 7.44 (m, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.29 (d, J = 7.7 Hz, 1H), 7.25–7.19 (m, 2H), 7.14 (t, J = 7.6 Hz, 1H), 2.40 (s, 3H), 2.09 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.8, 168.5, 142.0, 140.0, 134.0, 133.8, 132.1, 129.1, 128.6, 126.2, 124.7, 124.0, 123.8, 116.9, 115.3, 93.1, 20.5, 12.1. HRMS m/z (ESI+): calculated for C18H15INO3 ([M + H]+): 441.9911, found 441.9900.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.1 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.28 (m, 2H), 7.25–7.19 (m, 1H), 7.17–7.12 (m, 1H), 7.06 (dd, J = 8.0, 1.7 Hz, 1H), 2.40 (s, 3H), 2.35 (s, 3H), 2.11 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.9, 168.5, 141.8, 139.7, 139.0, 134.0, 133.7, 133.1, 129.7, 126.2, 124.7, 124.0, 123.7, 116.9, 115.3, 89.0, 20.9, 20.5, 12.1. HRMS m/z (ESI+): calculated for C19H16INO3Na ([M + Na]+): 456.0067, found 456.0058.
:
10 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.8 Hz, 1H), 7.36 (m, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.23 (m, 1H), 7.19–7.12 (m, 1H), 6.99 (d, J = 3.0 Hz, 1H), 6.83 (dd, J = 8.8, 3.1 Hz, 1H), 3.80 (s, 3H), 2.40 (s, 3H), 2.13 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 168.6, 168.5, 160.1, 142.7, 140.7, 134.0, 133.9, 126.2, 124.8, 124.0, 123.8, 118.9, 116.9, 115.3, 114.3, 81.4, 55.7, 20.5, 12.1. HRMS m/z (ESI+): calculated for C19H16INO4Na ([M + Na]+): 472.0016, found 472.0013.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.87 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 7.5 Hz, 1H), 7.27–7.24 (m, 1H), 7.19 (m, 2H), 7.03–6.97 (m, 1H), 2.40 (s, 3H), 2.11 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.4, 167.4, 162.8 (d, J = 250.0 Hz), 143.5 (d, J = 6.3 Hz), 141.6 (d, J = 7.5 Hz), 134.1, 133.9, 125.9, 124.9, 124.1, 124.0, 119.7 (d, J = 21.3 Hz), 117.1, 116.6 (d, J = 23.8 Hz), 115.2, 86.2 (d, J = 3.8 Hz), 20.5, 12.1. HRMS m/z (ESI+): calculated for C18H13FINO3Na ([M + Na]+): 459.9816, found 459.9805.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 1.9 Hz, 1H), 7.49 (m, 1H), 7.36 (m, 2H), 7.30 (d, J = 7.6 Hz, 1H), 7.25–7.21 (m, 1H), 7.19–7.14 (m, 1H), 2.40 (s, 3H), 2.11 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.4, 168.0, 140.4, 139.6, 137.3, 134.0, 133.9, 129.9, 129.0, 126.0, 124.8, 124.1, 123.9, 117.1, 115.1, 93.5, 20.5, 12.2. HRMS m/z (ESI+): calculated for C18H13ClINO3Na ([M + Na]+): 475.9521, found 475.9512.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 2.5 Hz, 1H), 7.40 (d, J = 6.6 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.26–7.21 (m, 2H), 7.19 (m, 1H), 2.40 (s, 3H), 2.11 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.4, 167.4, 143.4, 141.1, 135.3, 134.1, 133.9, 132.2, 129.0, 125.9, 124.9, 124.1, 124.0, 117.1, 115.2, 90.2, 20.5, 12.2. HRMS m/z (ESI+): calculated for C18H13ClINO3Na ([M + Na]+): 475.9521, found 475.9513.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.39 (s, 2H), 7.37 (d, J = 7.6 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 7.3 Hz, 1H), 7.22–7.19 (m, 1H), 7.15 (t, J = 7.5 Hz, 1H), 2.52 (s, 3H), 2.40 (s, 3H), 2.08 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 169.4, 168.5, 143.4, 143.3, 134.1, 133.8, 131.4, 128.7, 126.3, 126.1, 124.7, 124.0, 123.8, 116.9, 115.5, 99.6, 28.8, 20.5, 12.2. HRMS m/z (ESI+): calculated for C19H16INO3Na ([M + Na]+): 456.0067, found 456.0069.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 7.7 Hz, 1H), 7.49 (m, 1H), 7.44–7.41 (m, 1H), 7.25–7.15 (m, 2H), 7.09–6.90 (m, 2H), 2.40 (s, 3H), 2.39 (s, 3H), 2.08 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.7, 168.6, 142.1, 141.9, 139.9, 133.5, 132.3, 131.9, 129.0, 128.6, 128.0, 126.0, 124.2, 116.8, 115.0, 93.1, 21.3, 20.5, 12.1. HRMS m/z (ESI+): calculated for C19H16INO3Na ([M + Na]+): 456.0067, found 456.0060.
:
10 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 7.9 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.43 (m, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.23 (m, 1H), 6.77–6.70 (m, 2H), 3.82 (s, 3H), 2.40 (s, 3H), 2.05 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.5, 168.4, 156.6, 142.1, 139.9, 133.8, 131.9, 128.9, 128.59, 128.55, 126.8, 125.0, 116.4, 113.0, 99.9, 93.1, 55.6, 20.5, 12.2. HRMS m/z (ESI+): calculated for C19H16INO4Na ([M + Na]+): 472.0016, found 472.0006.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 7.6 Hz, 1H), 7.51 (td, J = 7.6, 0.8 Hz, 1H), 7.44 (dd, J = 7.6, 1.6 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.27 (d, J = 1.9 Hz, 1H), 7.26–7.24 (m, 1H), 7.11 (dd, J = 8.9, 2.1 Hz, 1H), 2.40 (s, 3H), 2.05 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.6, 168.4, 141.6, 140.0, 132.9, 132.4, 132.3, 129.6, 129.1, 128.7, 127.7, 125.3, 124.8, 116.8, 116.4, 93.0, 20.5, 12.2. HRMS m/z (ESI+): calculated for C18H13ClINO3Na ([M + Na]+): 475.9521, found 475.9515.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.95–7.91 (m, 1H), 7.52–7.49 (m, 1H), 7.44 (m, J = 7.6, 1.6 Hz, 2H), 7.25 (m, J = 7.6, 6.0 Hz, 1H), 6.96 (dd, J = 8.2, 2.6 Hz, 1H), 6.89 (td, J = 9.1, 2.6 Hz, 1H), 2.39 (s, 3H), 2.03 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.6, 168.3, 159.7 (d, J = 241.3 Hz), 141.8, 140.0, 133.4 (d, J = 3.8 Hz), 132.2, 130.3, 129.0, 128.6, 127.8, 125.2 (d, J = 8.8 Hz), 116.7 (d, J = 8.8 Hz), 112.4 (d, J = 23.8 Hz), 103.0 (d, J = 25.0 Hz), 93.0, 20.5, 12.2. HRMS m/z (ESI+): calculated for C18H13FINO3Na ([M + Na]+): 459.9816, found 459.9813.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 7.7 Hz, 1H), 7.51 (td, J = 7.5, 0.7 Hz, 1H), 7.46–7.41 (m, 2H), 7.28–7.23 (m, 3H), 2.40 (s, 3H), 2.05 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.6, 168.3, 141.6, 140.0, 132.7, 132.7, 132.3, 129.1, 128.7, 127.6, 127.5, 125.7, 119.8, 117.2, 116.7, 93.0, 20.5, 12.1. HRMS m/z (ESI+): calculated for C18H13BrINO3Na ([M + Na]+): 519.9016, found 519.9003.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.97–7.92 (m, 1H), 7.57 (s, 1H), 7.55–7.50 (m, 1H), 7.46 (dd, J = 7.8, 1.5 Hz, 2H), 7.42–7.38 (m, 1H), 7.30–7.26 (m, 1H), 2.43 (s, 3H), 2.10 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.8, 168.4, 141.4, 140.2, 135.5, 133.4, 132.5, 129.3, 128.8, 128.3, 126.1 (q, J = 32.5 Hz), 124.4 (q, J = 270.0 Hz), 123.9, 121.5 (q, J = 3.8 Hz), 115.5, 114.6 (q, J = 5.0 Hz), 93.0, 20.5, 12.2. HRMS m/z (ESI+): calculated for C19H13F3INO3Na ([M + Na]+): 509.9784, found 509.9776.
:
5 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 8.02 (d, J = 1.2 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.85 (dd, J = 8.8, 1.6 Hz, 1H), 7.52 (t, J = 7.4 Hz, 1H), 7.47 (m, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.27 (m, 1H), 3.92 (s, 3H), 2.43 (s, 3H), 2.11 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.7, 168.4, 166.9, 141.4, 140.1, 136.5, 133.6, 132.4, 129.2, 128.7, 127.8, 125.9, 125.6, 123.9, 119.1, 114.8, 93.0, 52.1, 20.5, 12.1. HRMS m/z (ESI+): calculated for C20H16INO5Na ([M + Na]+): 499.9965, found 499.9953.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.94–7.91 (m, 1H), 7.50–7.41 (m, 3H), 7.23 (m, 1H), 7.17 (d, J = 7.9 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 2.38 (s, 3H), 2.35 (s, 3H), 1.96 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.9, 168.4, 142.1, 139.8, 134.9, 134.5, 134.0, 131.9, 129.0, 128.5, 125.2, 124.9, 121.7, 116.5, 116.0, 93.2, 22.0, 20.5, 12.1. HRMS m/z (ESI+): calculated for C19H16INO3Na ([M + Na]+): 456.0067, found 456.0059.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 7.7 Hz, 1H), 7.65 (s, 1H), 7.50 (m, 1H), 7.43 (m, 1H), 7.27–7.19 (m, 3H), 2.37 (s, 3H), 1.95 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.6, 168.3, 141.5, 139.9, 134.3, 133.4, 132.2, 130.8, 129.0, 128.6, 126.5, 124.4, 122.5, 117.7, 115.9, 93.0, 20.4, 12.1. HRMS m/z (ESI+): calculated for C18H13ClINO3Na ([M + Na]+): 475.9521, found 475.9512.
:
20 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 7.9 Hz, 1H), 7.52 (m, 1H), 7.44 (m, 1H), 7.28 (d, J = 1.5 Hz, 1H), 7.26–7.19 (m, 2H), 7.00 (td, J = 8.8, 2.2 Hz, 1H), 2.39 (s, 3H), 2.00 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 168.6, 168.3, 160.9 (d, J = 240.0 Hz), 141.5, 139.9, 134.1 (d, J = 11.3 Hz), 133.3, 132.2, 128.7 (d, J = 40.0 Hz), 126.1, 126.0, 120.3, 117.6 (d, J = 10.0 Hz), 111.9 (d, J = 23.8 Hz), 103.2 (d, J = 28.8 Hz), 92.9, 20.4, 12.0. HRMS m/z (ESI+): calculated for C18H13FINO3Na ([M + Na]+): 459.9816, found 459.9809.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.0 Hz, 1H), 7.83 (m, 2H), 7.78–7.73 (m, 2H), 7.73–7.68 (m, 1H), 7.53 (m, 1H), 7.29 (t, J = 7.5 Hz, 1H), 1.81 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 197.4, 169.6, 151.7, 145.6, 137.4, 134.4, 131.1, 129.5, 127.5, 125.3, 125.24, 125.16, 122.8, 118.6, 73.6, 25.9. HRMS m/z (ESI+): calculated for C16H11NO2Na ([M + Na]+): 272.0682, found 272.0672. For the reaction with (R,R,R)-phosphoramide-PE as a chiral ligand: 30% yield, 63% ee [Daicel Chiralpak AD-H column (25 cm × 0.46 cm ID), nhexane/iPrOH = 95/5, 0.7 mL min−1, 254 nm; tmajor = 18.6 min, tminor = 21.4 min].
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.1 Hz, 1H), 7.78–7.72 (m, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.64 (s, 1H), 7.53–7.50 (m, 1H), 7.29 (d, J = 7.4 Hz, 1H), 2.44 (s, 3H), 1.78 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 197.8, 169.9, 151.8, 143.1, 139.9, 137.4, 135.6, 131.3, 127.6, 125.4, 125.3, 125.2, 122.5, 118.7, 73.5, 26.0, 21.4. HRMS m/z (ESI+): calculated for C17H14NO2 ([M + H]+): 264.1019, found 264.1016.
:
10 (v/v); Rf = 0.4. 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.0 Hz, 1H), 7.79–7.73 (m, 2H), 7.70 (d, J = 8.4 Hz, 1H), 7.31–7.27 (m, 2H), 7.27–7.25 (m, 1H), 3.86 (s, 3H), 1.77 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 197.7, 169.8, 161.1, 151.6, 138.2, 137.4, 132.5, 127.8, 125.4, 125.2, 123.7, 122.9, 118.7, 107.6, 73.3, 55.8, 25.9. HRMS m/z (ESI+): calculated for C17H13NO3Na ([M + Na]+): 302.0788, found 302.0788.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 7.9 Hz, 1H), 7.78 (m, 3H), 7.50 (dd, J = 7.4, 2.4 Hz, 1H), 7.41 (td, J = 8.6, 2.4 Hz, 1H), 7.34–7.28 (m, 1H), 1.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 197.0, 168.43, 168.41, 163.6 (d, J = 248.8 Hz), 151.3, 141.2 (d, J = 1.3 Hz), 137.5, 133.3 (d, J = 7.5 Hz), 127.5, 125.4 (d, J = 6.3 Hz), 124.4 (d, J = 8.8 Hz), 122.1, 121.9, 118.6, 111.7 (d, J = 22.5 Hz), 73.2, 25.9. HRMS m/z (ESI+): calculated for C16H11FNO2 ([M + H]+): 268.0768, found 268.0768.
:
20 (v/v); Rf = 0.4. 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 1.6 Hz, 1H), 7.76 (m, 3H), 7.50 (dd, J = 8.2, 1.8 Hz, 1H), 7.30 (m, 1H), 1.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.7, 168.5, 151.5, 147.0, 141.1, 137.6, 130.3, 129.6, 127.3, 126.4, 125.4, 123.3, 118.6, 73.1, 25.9. HRMS m/z (ESI+): calculated for C16H11ClNO2 ([M + H]+): 284.0473, found 284.0466.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 1.8 Hz, 1H), 7.79–7.74 (m, 3H), 7.67 (m, 1H), 7.31 (t, J = 7.5 Hz, 1H), 1.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.8, 168.2, 151.3, 143.7, 137.6, 136.0, 134.5, 132.9, 127.5, 125.5, 125.4, 125.2, 124.0, 118.6, 73.3, 25.9. HRMS m/z (ESI+): calculated for C16H10ClNO2Na ([M + Na]+): 306.0292, found 306.0286.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.0 Hz, 1H), 7.78–7.71 (m, 2H), 7.68 (d, J = 7.5 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.28 (t, J = 5.0 Hz, 1H), 2.84 (s, 3H), 1.88 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 197.5, 169.0, 150.7, 143.5, 137.3, 136.5, 135.0, 132.0, 129.4, 127.8, 125.2, 125.0, 122.6, 118.3, 74.9, 24.4, 19.3. HRMS m/z (ESI+): calculated for C17H14NO2 ([M + H]+): 264.1019, found 264.1011.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.89–7.78 (m, 3H), 7.69 (t, J = 7.5 Hz, 1H), 7.56 (d, J = 8.5 Hz, 2H), 7.52 (t, J = 7.5 Hz, 1H), 2.40 (s, 3H), 1.79 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 197.4, 169.6, 149.7, 145.6, 138.4, 135.2, 134.2, 131.2, 129.4, 127.6, 125.1, 125.0, 122.7, 118.2, 73.8, 25.9, 20.9. HRMS m/z (ESI+): calculated for C17H13NO2Na ([M + Na]+): 286.0838, found 286.0829.
:
10 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 8.8 Hz, 1H), 7.82 (dd, J = 14.8, 7.7 Hz, 2H), 7.70 (td, J = 7.7, 1.0 Hz, 1H), 7.53 (m, 1H), 7.35 (dd, J = 8.8, 2.7 Hz, 1H), 7.19 (d, J = 2.7 Hz, 1H), 3.83 (s, 3H), 1.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 197.5, 169.9, 157.5, 146.2, 145.5, 134.3, 131.2, 129.5, 128.3, 126.1, 125.2, 122.7, 119.6, 106.5, 74.3, 55.9, 25.9. HRMS m/z (ESI+): calculated for C17H13NO3Na ([M + Na]+): 302.0788, found 302.0778.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 8.5 Hz, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.80 (d, J = 7.7 Hz, 1H), 7.74–7.68 (m, 3H), 7.57–7.52 (m, 1H), 1.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.4, 169.5, 150.1, 145.4, 137.3, 134.7, 131.2, 130.9, 129.8, 128.8, 125.5, 125.0, 122.8, 119.8, 74.2, 26.0. HRMS m/z (ESI+): calculated for C16H11ClNO2 ([M + H]+): 325.2420, found 325.2411.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.96 (dd, J = 8.8, 4.1 Hz, 1H), 7.83 (m, 2H), 7.74–7.70 (m, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.48 (td, J = 8.7, 2.7 Hz, 1H), 7.43 (dd, J = 6.9, 2.7 Hz, 1H), 1.81 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.8, 169.7, 160.1 (d, J = 246.3 Hz), 148.0, 145.4, 134.6, 131.0, 129.7, 128.7 (d, J = 8.8 Hz), 125.4, 124.8 (d, J = 25.0 Hz), 122.8, 120.0 (d, J = 7.5 Hz), 111.1 (d, J = 23.8 Hz), 74.4, 25.9. HRMS m/z (ESI+): calculated for C16H11FNO2 ([M + H]+): 268.0768, found 268.0762.
:
20 (v/v); Rf = 0.4. 1H NMR (500 MHz, CDCl3) δ 7.88 (m, 2H), 7.86–7.82 (m, 2H), 7.80 (d, J = 7.7 Hz, 1H), 7.72 (td, J = 7.6, 0.9 Hz, 1H), 7.55 (m, 1H), 1.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.2, 169.4, 150.5, 145.3, 140.0, 134.7, 130.9, 129.7, 129.2, 128.0, 125.4, 122.8, 120.1, 118.4, 73.9, 25.9. HRMS m/z (ESI+): calculated for C16H10BrNO2Na ([M + Na]+): 349.9787, found 349.9796.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J = 8.5 Hz, 1H), 8.05 (s, 1H), 8.00 (dd, J = 8.4, 1.5 Hz, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.75 (m, 1H), 7.59–7.54 (m, 1H), 1.83 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.4, 169.2, 153.7, 145.3, 134.9, 134.1 (q, J = 3.8 Hz), 130.7, 129.9, 127.7, 127.6 (q, J = 33.8 Hz), 125.6, 124.6, 122.88, 122.85, 119.0, 74.1, 26.0. HRMS m/z (ESI+): calculated for C17H10F3NO2Na ([M + Na]+): 347.2224, found 347.2226.
:
10 (v/v); Rf = 0.2. 1H NMR (500 MHz, CDCl3) δ 8.47–8.41 (m, 2H), 8.03 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.76–7.71 (m, 1H), 7.56 (m, 1H), 3.95 (s, 3H), 1.82 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.6, 169.1, 165.7, 154.4, 145.5, 138.5, 134.8, 130.8, 129.8, 127.6, 127.3, 127.2, 125.5, 122.8, 118.2, 74.1, 52.5, 26.1. HRMS m/z (ESI+): calculated for C18H14NO4 ([M + H]+): 308.0917, found 308.0903.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.87–7.78 (m, 3H), 7.70 (td, J = 7.7, 1.0 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.53 (m, 1H), 7.10 (d, J = 7.8 Hz, 1H), 2.52 (s, 3H), 1.79 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.8, 169.7, 152.0, 149.5, 145.8, 134.3, 131.2, 129.4, 126.5, 125.2, 125.1, 125.0, 122.7, 118.8, 73.9, 26.1, 22.6. HRMS m/z (ESI+): calculated for C17H14NO2 ([M + H]+): 264.1019, found 264.1009.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 1.6 Hz, 1H), 7.86 (d, J = 7.7 Hz, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.73 (m, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.56–7.53 (m, 1H), 7.26 (m, 1H), 1.80 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 196.2, 169.4, 152.3, 145.6, 144.0, 134.7, 130.8, 129.7, 126.2, 125.92, 125.90, 125.5, 122.8, 118.9, 74.0, 26.0. HRMS m/z (ESI+): calculated for C16H10ClNO2Na ([M + Na]+): 306.0292, found 306.0280.
:
20 (v/v); Rf = 0.3. 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 7.6 Hz, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.77 (dd, J = 8.5, 5.5 Hz, 1H), 7.72 (t, J = 7.5 Hz, 1H), 7.66 (dd, J = 8.9, 2.1 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 6.98 (td, J = 8.6, 2.1 Hz, 1H), 1.81 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 195.7, 169.4, 168.7 (d, J = 256.3 Hz), 153.6 (d, J = 13.8 Hz), 145.7, 134.7, 130.7, 129.6, 127.4 (d, J = 12.5 Hz), 125.4, 123.7, 122.8, 113.4 (d, J = 23.8 Hz), 106.1 (d, J = 26.3 Hz), 74.2, 26.0. HRMS m/z (ESI+): calculated for C16H11FNO2 ([M + H]+): 279.2795, found 279.2784.
Footnote |
| † Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra02569c |
| This journal is © The Royal Society of Chemistry 2019 |